Edwards Lifesciences is a global leader in innovative medical technology, specializing in heart valve repair and replacement, as well as critical care monitoring. The company focuses on developing advanced products to enhance the quality of heart surgery and improve patient outcomes. Edwards Lifesciences is dedicated to addressing cardiovascular disease, which remains a leading cause of death worldwide, by providing solutions that enable less invasive procedures and better management of patients with heart-related conditions. Through continuous research and development, the company strives to transform patient care in the fields of heart disease and surgical intervention. Read More
Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top S&P500 gainers and losers in today's pre-market session.
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top S&P500 gainers and losers driving the post-market movements.
Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2025 after the market closes on Thursday July 24, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results.
The company said in a regulatory filing that the decision was made in light of increased clinical and regulatory requirements to maintain regulatory approvals in global markets and to obtain approvals in new regions.
Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, further contributing to the extensive body of research on this disease.
Edwards Lifesciences (NYSE:EW) shows strong technicals and a consolidation pattern, making it a breakout candidate. Resistance at $76.76 could signal further upside if broken.
Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for severe aortic stenosis (AS) patients without symptoms, marking the first FDA approval for TAVR in asymptomatic patients.
